Leveraging Innovation To Deliver Precision Medicines

Pipeline

PAD4

Strong scientific and clinical rationale for PAD4 inhibitors in autoimmune disorders

Rationale

  • Next generation target in autoimmune/inflammation beyond JAKs and TNFs
  • High anti-CCP (anti-cyclic citrullinated peptide) levels are detected in RA patients
  • Histone citrullination and associated NET formation linked to pro-inflammation and disease progression in several autoimmune disorders including RA, psoriasis, thrombosis, fibrosis, SLE etc
  • KO studies clearly prove the role of PAD4 in RA, SLE, DVT etc
  • Targeting PAD4 does not lead to immune suppression nor risk of thrombocytopenia and may offer better therapeutic margin and safety
  • Antibodies produced against citrullinated proteins (anti-CCP) are diagnostic, prognostic and stratification markers of RA
  • Potential to target inflammation-driven diseases

Opportunity

  • Differentiated first-in-class mechanism to treat autoimmune diseases
  • Broader application in various auto-immune disorders such as lung fibrosis (including Covid-19 ARDS), psoriasis, SLE, DVT
  • Potential utility in niche indications such as Bullous Pemphigoid and Behcet’s diseases

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.